Pfizer CEO Dr. Albert Bourla speaks to CNN’s Meg Tirrell about pushing past vaccine skepticism to work with the Trump ...

The Centers for Disease Control and Prevention says children without underlying health conditions "may receive" a COVID-19 ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

The FDA approved the poly ADP ribose polymerase (PARP) inhibitor in June 2023 in combination with enzalutamide for men with ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

A colorectal cancer drug from Pfizer Inc. doubled survival time compared to the standard of care for a subset of patients, ...

Pfizer's BRAFTOVI combo cut death risk by 51% and more than doubled survival in BRAF-mutant colorectal cancer in a Phase 3 ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

Pfizer (PFE) stock gains as Braftovi combo shows survival benefits in a late-stage trial for metastatic colorectal cancer ...

Cancer remains one of the biggest health challenges of our lifetime. Millions of people globally receive a cancer diagnosis each year — in the United States, that’s about one diagnosis every 30 ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

Phase III progression-free survival data were positive for first-line Braftovi in first-line combination therapy for mCRC.